Wunderlich Securities: Future Looks Solid for Stryker

In a research report published this morning by Wunderlich Securities, Stryker

will report its 1Q results after the close today. According to Wunderlich Securities, "While the macro environment remains challenging and orthopedic procedure trends remain lackluster (but seemingly stable), we expect SYK to post a solid quarter. Our EPS of $0.99 is in line with Street consensus, and we believe the potential for meaningful surprise in Q1 is rather low. Longer term, we remain optimistic about SYK's outlook despite the challenging environment, as recent acquisitions turn increasingly accretive and late 2011 restructuring moves allow for meaningful expense reductions. As a result, we believe SYK is one of the better positioned large cap MedTech companies; SYK remains on our Best Ideas List." Wunderlich Securities maintains its Buy rating and $66 PT on Stryker, which closed yesterday at $54.24.